Targets the aging pathway directly.
Sirolimus inhibits mTOR, a key regulator of cellular growth and aging. Low, intermittent dosing promotes autophagy — the cellular cleanup process tied to longevity.

Longevity & Cognition
An mTOR inhibitor, dosed low and intermittently, researched for cellular cleanup and long-term healthspan.
Select treatment cycle
Total due now
$483.30
$161.10 per month · 3 Months
Prescription items are subject to physician review before dispensing. Once you check out, you'll get member portal access to complete a medical intake form. A licensed physician reviews it, and if you're approved, your medication ships. Your provider sets the exact dose during that review.
This is a prescription product and requires an evaluation by a licensed provider. Purchase does not guarantee a prescription; if you are not approved, you will not be charged for medication. Compounded formulations are prepared by licensed 503A pharmacies and are not FDA-approved for safety or efficacy. Availability varies by state. Not for use by anyone under 18. This information is not medical advice — talk to your provider about risks, side effects, and interactions.
Multi-month plans renew automatically at the end of the term until cancelled. Cancel anytime before renewal at support@getargorx.com or (279) 348-3430.
Understand the protocol

Sirolimus (Rapamycin)
Sirolimus inhibits mTOR, a key regulator of cellular growth and aging. Low, intermittent dosing promotes autophagy — the cellular cleanup process tied to longevity.
Healthy adults pursuing evidence-based longevity intervention, patients focused on healthspan and cellular aging, always under clinician supervision with periodic labs.
Sirolimus isn't a symptom drug — most patients feel nothing acute. Benefits show up through inflammatory markers, metabolic labs and biological age over six to twelve months.
Weekly dosing begins low. Mouth sores or mild GI upset are the side effects to watch for.
Follow-up bloodwork checks lipids, glucose and blood counts before the dose is held or adjusted.
Recovery, joint comfort and inflammatory markers are the practical read. Benefits here are cumulative, not dramatic.
This is a longevity protocol measured in years, with routine monitoring throughout.
Timelines are typical ranges reported in clinical use and by Argo patients. Individual results vary with dose, adherence, baseline health and lifestyle.
Weekly
Intermittent dosing
mTOR
Pathway targeted
Lab-tracked
How results show

Fog has a short list of causes. We check all of them.
Fog has a short list of causes. We check all of them.
